Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

Xinyue CUI; Quanhao SUN; Lihong ZHENG; Haiqiang WANG

doi:10.12449/JCH250228

Volume 41 Issue 2

Feb. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(2): 383-388

PDF( 634 KB)

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

DOI: 10.12449/JCH250228

1.
The First Clinical College of Heilongjiang University of Chinese Medicine，Harbin 150040，China
2.
Department of Gastroenterology，The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150001，China
3.
Second Department of Gastroenterology，The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150040，China

Research funding:

State Administration of Traditional Chinese Medicine, the Fifth Batch of National Chinese Medicine Clinical Excellence Training Program (the State Administration of Traditional Chinese Medicine Human Education Letter ［2022］ No.1);

Heilongjiang University of Traditional Chinese Medicine “Outstanding Young Backbone Teachers” Program (15041190018)

More Information

Corresponding author: WANG Haiqiang， haiqiang915@163.com （ORCID： 0000-0002-1183-0283）
Received Date: 2024-06-03
Accepted Date: 2024-06-20
Published Date: 2025-02-25

Abstract

Abstract

Triggering receptor expressed on myeloid cells 2 （TREM2） is expressed in resident non-parenchymal cells （NPCs） and is involved in various pathological processes including liver inflammation and immunoregulation. In recent years， TREM2 has attracted attention in the field of acute and chronic liver diseases， and more and more studies have shown that TREM2 is a potential target for the treatment of acute and chronic liver diseases； however， there is a lack of systematic summary for the mechanism of action of TREM2 in acute and chronic liver diseases. Therefore， this article reviews the latest research advances in the regulatory role of TREM2 in acute and chronic liver diseases， in order to provide new ideas for the clinical prevention and treatment of acute and chronic liver diseases.
- Triggering Receptor Expressed on Myeloid Cells 2,
- Liver Diseases,
- Pathologic Processes

FullText(HTML)

致谢: 感谢王华庆、王潇滟、乔建荣、任明辉、庄辉、李增德、周脉耕、郑徽、徐小元、梁晓峰等专家对本文撰写提供的支持和帮助。

References(47)

References

[1]	COLONNA M. The biology of TREM receptors[J]. Nat Rev Immunol, 2023, 23( 9): 580- 594. DOI: 10.1038/s41577-023-00837-1.
[2]	ULLAND TK, SONG WM, HUANG SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease[J]. Cell, 2017, 170( 4): 649- 663. e 13. DOI: 10.1016/j.cell.2017.07.023.
[3]	SUN HF, FENG JG, TANG LL. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9( 12): 2626. DOI: 10.3390/cells9122626.
[4]	HENDRIKX T, PORSCH F, KISS MG, et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2⁺ macrophages that localize to fibrotic areas and limit NASH[J]. J Hepatol, 2022, 77( 5): 1373- 1385. DOI: 10.1016/j.jhep.2022.06.004.
[5]	INDIRA CHANDRAN V, WERNBERG CW, LAURIDSEN MM, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness[J]. Hepatology, 2023, 77( 2): 558- 572. DOI: 10.1002/hep.32620.
[6]	PERUGORRIA MJ, ESPARZA-BAQUER A, OAKLEY F, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage[J]. Gut, 2019, 68( 3): 533- 546. DOI: 10.1136/gutjnl-2017-314107.
[7]	XIONG XL, KUANG H, ANSARI S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis[J]. Mol Cell, 2019, 75( 3): 644- 660. e 5. DOI: 10.1016/j.molcel.2019.07.028.
[8]	GOVAERE O, COCKELL S, TINIAKOS D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med, 2020, 12( 572): eaba4448. DOI: 10.1126/scitranslmed.aba4448.
[9]	ESPARZA-BAQUER A, LABIANO I, SHARIF O, et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms[J]. Gut, 2021, 70( 7): 1345- 1361. DOI: 10.1136/gutjnl-2019-319227.
[10]	MOLGORA M, ESAULOVA E, VERMI W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy[J]. Cell, 2020, 182( 4): 886- 900. e 17. DOI: 10.1016/j.cell.2020.07.013.
[11]	HAN S, LI XD, XIA N, et al. Myeloid Trem2 dynamically regulates the induction and resolution of hepatic ischemia-reperfusion injury inflammation[J]. Int J Mol Sci, 2023, 24( 7): 6348. DOI: 10.3390/ijms24076348.
[12]	LANIER LL, CORLISS BC, WU J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells[J]. Nature, 1998, 391( 6668): 703- 707. DOI: 10.1038/35642.
[13]	ULLAND TK, COLONNA M. TREM2—a key player in microglial biology and Alzheimer disease[J]. Nat Rev Neurol, 2018, 14: 667- 675. DOI: 10.1038/s41582-018-0072-1.
[14]	PENG QS, MALHOTRA S, TORCHIA JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1[J]. Sci Signal, 2010, 3( 122): ra38. DOI: 10.1126/scisignal.2000500.
[15]	KOBER DL, BRETT TJ. TREM2-ligand interactions in health and disease[J]. J Mol Biol, 2017, 429( 11): 1607- 1629. DOI: 10.1016/j.jmb.2017.04.004.
[16]	HAMERMAN JA, JARJOURA JR, HUMPHREY MB, et al. Cutting edge: Inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells(TREM)-2 and DAP12[J]. J Immunol, 2006, 177( 4): 2051- 2055. DOI: 10.4049/jimmunol.177.4.2051.
[17]	PALONEVA J, MANDELIN J, KIIALAINEN A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features[J]. J Exp Med, 2003, 198( 4): 669- 675. DOI: 10.1084/jem.20030027.
[18]	BHARADWAJ S, GROZA Y, MIERZWICKA JM, et al. Current understanding on TREM-2 molecular biology and physiopathological functions[J]. Int Immunopharmacol, 2024, 134: 112042. DOI: 10.1016/j.intimp.2024.112042.
[19]	KHANTAKOVA D, BRIOSCHI S, MOLGORA M. Exploring the impact of TREM2 in tumor-associated macrophages[J]. Vaccines(Basel), 2022, 10( 6): 943. DOI: 10.3390/vaccines10060943.
[20]	FEUERBACH D, SCHINDLER P, BARSKE C, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells(hTREM2) ectodomain and cleaves TREM2 after Histidine 157[J]. Neurosci Lett, 2017, 660: 109- 114. DOI: 10.1016/j.neulet.2017.09.034.
[21]	NI M, ZHANG J, SOSA R, et al. T-cell immunoglobulin and mucin domain-containing protein-4 is critical for kupffer cell homeostatic function in the activation and resolution of liver ischemia reperfusion injury[J]. Hepatology, 2021, 74( 4): 2118- 2132. DOI: 10.1002/hep.31906.
[22]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
[23]	LEUNG PB, DAVIS AM, KUMAR S. Diagnosis and management of nonalcoholic fatty liver disease[J]. JAMA, 2023, 330( 17): 1687- 1688. DOI: 10.1001/jama.2023.17935.
[24]	LIEBOLD I, MEYER S, HEINE M, et al. TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD[J]. Cells, 2023, 12( 3): 341. DOI: 10.3390/cells12030341.
[25]	DAWS MR, SULLAM PM, NIEMI EC, et al. Pattern recognition by TREM-2: Binding of anionic ligands[J]. J Immunol, 2003, 171( 2): 594- 599. DOI: 10.4049/jimmunol.171.2.594.
[26]	TURNBULL IR, GILFILLAN S, CELLA M, et al. Cutting edge: TREM-2 attenuates macrophage activation[J]. J Immunol, 2006, 177( 6): 3520- 3524. DOI: 10.4049/jimmunol.177.6.3520.
[27]	WANG XC, HE QF, ZHOU CL, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development[J]. Immunity, 2023, 56( 1): 58- 77. e 11. DOI: 10.1016/j.immuni.2022.11.013.
[28]	HOU JC, ZHANG J, CUI P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis[J]. J Clin Invest, 2021, 131( 4): e135197. DOI: 10.1172/JCI135197.
[29]	ZHOU LK, QIU XX, MENG ZY, et al. Hepatic danger signaling triggers TREM2⁺ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation[J]. Sci Transl Med, 2024, 16( 738): eadk1866. DOI: 10.1126/scitranslmed.adk1866.
[30]	WOOLBRIGHT BL, JAESCHKE H. Inflammation and cell death during cholestasis: The evolving role of bile acids[J]. Gene Expr, 2019, 19( 3): 215- 228. DOI: 10.3727/105221619X15614873062730.
[31]	de VRIES E, BEUERS U. Management of cholestatic disease in 2017[J]. Liver Int, 2017, 37( Suppl 1): 123- 129. DOI: 10.1111/liv.13306.
[32]	LABIANO I, AGIRRE-LIZASO A, OLAIZOLA P, et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation[J]. J Hepatol, 2022, 77( 4): 991- 1004. DOI: 10.1016/j.jhep.2022.05.044.
[33]	IREDALE JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest, 2007, 117( 3): 539- 548. DOI: 10.1172/JCI30542.
[34]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
[35]	RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575( 7783): 512- 518. DOI: 10.1038/s41586-019-1631-3.
[36]	ZHU DD, HUANG M, SHEN P, et al. TREM2 expression promotes liver and peritoneal M2 macrophage polarization in mice infected with Schistosoma japonicum[J]. J Cell Mol Med, 2023, 27( 15): 2261- 2269. DOI: 10.1111/jcmm.17842.
[37]	YE ZH, HUANG SG, ZHANG YX, et al. Galectins, eosinophiles, and macrophages may contribute to Schistosoma japonicum egg-induced immunopathology in a mouse model[J]. Front Immunol, 2020, 11: 146. DOI: 10.3389/fimmu.2020.00146.
[38]	SHAN S, CHAO S, LIU Z, et al. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis[J]. Free Radic Biol Med, 2024, 220: 154- 165. DOI: 10.1016/j.freeradbiomed.2024.05.004.
[39]	MANTOVANI A, MARCHESI F, MALESCI A, et al. Tumour-associated macrophages as treatment targets in oncology[J]. Nat Rev Clin Oncol, 2017, 14( 7): 399- 416. DOI: 10.1038/nrclinonc.2016.217.
[40]	DENARDO DG, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19( 6): 369- 382. DOI: 10.1038/s41577-019-0127-6.
[41]	CASSETTA L, POLLARD JW. Targeting macrophages: Therapeutic approaches in cancer[J]. Nat Rev Drug Discov, 2018, 17( 12): 887- 904. DOI: 10.1038/nrd.2018.169.
[42]	WANG QY, ZHENG K, TAN D, et al. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2022, 636( Pt 1): 140- 146. DOI: 10.1016/j.bbrc.2022.10.079.
[43]	ZHOU LS, WANG ML, GUO HR, et al. Integrated analysis highlights the immunosuppressive role of TREM2⁺ macrophages in hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 848367. DOI: 10.3389/fimmu.2022.848367.
[44]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[45]	PALMER DH, MALAGARI K, KULIK LM. Role of locoregional therapies in the wake of systemic therapy[J]. J Hepatol, 2020, 72( 2): 277- 287. DOI: 10.1016/j.jhep.2019.09.023.
[46]	SUN YF, WU L, ZHONG Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184( 2): 404- 421. e 16. DOI: 10.1016/j.cell.2020.11.041.
[47]	TAN JZ, FAN WZ, LIU T, et al. TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J]. J Hepatol, 2023, 79( 1): 126- 140. DOI: 10.1016/j.jhep.2023.02.032.

Relative Articles

[1]	Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810
[2]	Manman XU, Nan GENG, Yu CHEN. An excerpt of EASL clinical practice guidelines on acute－on－chronic liver failure （2023）[J]. Journal of Clinical Hepatology, 2023, 39(10): 2321-2327. doi: 10.3969/j.issn.1001-5256.2023.10.008
[3]	Huimin LIU, Wenting CHEN, Shilian LI, Hongmei GONG, Qing. MAO. Key points of EASL Clinical Practice Guidelines on hepatitis delta virus （2023）[J]. Journal of Clinical Hepatology, 2023, 39(11): 2558-2563. doi: 10.3969/j.issn.1001-5256.2023.11.007
[4]	Dandan JIA, Guiying ZHU, Shiyao LIAO, Hui ZHANG, Hui GUO, Lili YANG, Changmiao WANG. Interpretation of European Society for Clinical Nutrition and Metabolism practical guideline : Clinical nutrition in liver disease (2020)[J]. Journal of Clinical Hepatology, 2021, 37(7): 1553-1557. doi: 10.3969/j.issn.1001-5256.2021.07.015
[5]	YANG Jia, RAO HuiYing. EASL recommendations on treatment of hepatitis C: Final update of the series (2020)[J]. Journal of Clinical Hepatology, 2020, 36(12): 2681-2687. doi: 10.3969/j.issn.1001-5256.2020.12.009
[6]	Yu LeCheng, Lai RongTao, Chen ChengWei. Key points and interpretation of EASL clinical practice guidelines: Drug-induced liver injury (2019)[J]. Journal of Clinical Hepatology, 2019, 35(6): 1242-1250. doi: 10.3969/j.issn.1001-5256.2019.06.013
[7]	Zhou YiXia, Gao Ya, Li Wu. An excerpt of EASL Clinical Practice Guidelines on nutrition in chronic liver disease (2018)[J]. Journal of Clinical Hepatology, 2018, 34(11): 2305-2310. doi: 10.3969/j.issn.1001-5256.2018.11.008
[8]	Yang Jia, Rao HuiYing, Wei Lai. Introduction and interpretation of EASL recommendations on treatment of hepatitis C 2018[J]. Journal of Clinical Hepatology, 2018, 34(8): 1622-1631. doi: 10.3969/j.issn.1001-5256.2018.08.007
[9]	Song Yang, Zhou Fei, Chen LiGang. An excerpt of EASL clinical practice guidelines: Management of alcohol-related liver disease (2018)[J]. Journal of Clinical Hepatology, 2018, 34(7): 1415-1419. doi: 10.3969/j.issn.1001-5256.2018.07.010
[10]	Ge NingLing, Xue TongChun, Ye ShengLong. Interpretation of EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (2018)[J]. Journal of Clinical Hepatology, 2018, 34(6): 1187-1190. doi: 10.3969/j.issn.1001-5256.2018.06.011
[11]	Yu JiongJie, Yan WenTao, Quan Bing, Yang Tian. Recommendations for EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (2018)[J]. Journal of Clinical Hepatology, 2018, 34(6): 1183-1186. doi: 10.3969/j.issn.1001-5256.2018.06.010
[12]	Li Yan, Tang ShanHong. An excerpt of EASL clinical practice guidelines on hepatitis E virus infection 2018[J]. Journal of Clinical Hepatology, 2018, 34(7): 1410-1414. doi: 10.3969/j.issn.1001-5256.2018.07.009
[13]	Yu LeCheng, Hou JinLin. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. Journal of Clinical Hepatology, 2017, 33(6): 1017-1032. doi: 10.3969/j.issn.1001-5256.2017.06.002
[14]	Yang Min, Zhang ShengGuo, Lu MingQin. EASL clinical practical guidelines on the management of acute(fulminant) liver failure(2017)[J]. Journal of Clinical Hepatology, 2017, 33(10): 1883-1887. doi: 10.3969/j.issn.1001-5256.2017.10.007
[15]	Huang Cheng, Sun HuiChuan. EASL clinical practice guidelines on the management of benign liver tumors (2016)[J]. Journal of Clinical Hepatology, 2016, 32(8): 1439-1445. doi: 10.3969/j.issn.1001-5256.2016.08.001
[16]	Gao Fan, Hu FengRong, Qi XingShun. An excerpt of 2015 EASL clinical practical guidelines: vascular diseases of the liver [J]. Journal of Clinical Hepatology, 2016, 32(1): 40-43. doi: 10.3969/j.issn.1001-5256.2016.01.005
[17]	Shen ShanShan, Dai MingJia, Yan XueBing. Interpretation and analysis of EASL recommendations on treatment of hepatitis C 2016[J]. Journal of Clinical Hepatology, 2016, 32(12): 2258-2262. doi: 10.3969/j.issn.1001-5256.2016.12.006
[19]	Chang BinXia, Li BaoSen, Zou ZhengSheng. An excerpt of EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease(2016)[J]. Journal of Clinical Hepatology, 2016, 32(8): 1450-1454. doi: 10.3969/j.issn.1001-5256.2016.08.003
[20]	Shi YingHong, Tian MengXin, Fan Jia. Recommendations for EASL clinical practice guidelines: liver transplantation（2015）[J]. Journal of Clinical Hepatology, 2016, 32(3): 429-431. doi: 10.3969/j.issn.1001-5256.2016.03.005

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (74) PDF downloads(7)

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

DOI: 10.12449/JCH250228

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

DOI: 10.12449/JCH250228

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content